Citations

Clear

355 citation(s) found for "Sherman, ME".

Wrist Arthrodesis with Scaphoid Autograft for Treatment of Extra-Axial Chordoma
Bechtle, Alexandra , Belancourt, Prianka , Sherman, Courtney E. , Aziz, Keith T.

Mayo Clinic

Journal of Wrist Surgery | March 6, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1055/a-2818-3173 Get It

Abstract Extra-axial chordoma (EAC) is a very rare, malignant tumor with metastatic potential that arises in the extra-axial skeleton and soft tissues. We report the case of a 51-year-old right-handed male with EAC of the left capitate. He underwent capitate resection and wrist arthrodesis utilizing scaphoid autograft with the treatment goal of minimizing risk of tumor recurrence and metastasis while maximizing hand and wrist function. His radiographic outcome demonstrated union of his arthrodesis site. However, 7 months postoperatively, he started experiencing increased hand and wrist pain and was found to have early tumor reoccurrence. Few cases of EAC have been reported in the literature. EAC is typically treated with resection alone, although there is a limited role for chemotherapy and radiation in the setting of locally reoccurring or metastatic disease. Functional outcomes of the affected extremity and survival outcomes vary widely. This is the first report in the literature of EAC of a single carpal bone and describes an innovative technique for definitive surgical treatment of this rare tumor. Utilization of scaphoid autograft for wrist arthrodesis in the setting of capitate resection allows the use of autograft in a wrist arthrodesis without the additional morbidity of iliac crest bone grafting. This case also demonstrates the importance of appropriate diagnosis and oncologic technique at the index surgery.
Abstract PS3-01-18: Gene expression signatures of beneficial response to tamoxifen for breast cancer prevention
Winham, S. J., Wang, C., Liu, Y., McCauley, B. M., Tabrizi, D. J., Gehling, D. L., Fischer, J. L., Seymour, L. R., Solanki, M. H., Sherman, M. E., Lohani, K. R., Hoskin, T. L., Radisky, D. C., Degnim, A. C., Winham, S., McCauley, Bryan M. , Gehling, Denice, Seymour, Lisa R. , Sherman, Mark E. , Hoskin, TL, Radisky, Derek C. , Degnim, A.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS3-01-18-PS3-01-18

10.1158/1557-3265.sabcs25-ps3-01-18 Get It

Abstract Uptake of tamoxifen is limited to 5-15% of all eligible women due to concerns regarding medication side effects combined with the lack of ability to predict which women will benefit from the therapies. We used a unique retrospective sample of n=92 high-risk women with paired benign biopsies obtained before (PreTam) and during tamoxifen (OnTam) to discover tissue gene expression biomarkers of biologic response, defined as change (Δ) in lobular Ki67. Ki67 was digitally quantified in normal lobules from PreTam and OnTam benign tissue samples and samples with PreTam Ki67 = 0 were excluded. Data were analyzed from 51 women with both PreTam and OnTam Ki67 (median age = 49 years and median BMI = 25.5 kg/m2 at PreTam biopsy). OnTam biopsies were collected a median of 11.5 months after PreTam biopsy (median 6.5 months after starting tamoxifen; dose 20 mg/day in 86%). Median Ki67 significantly decreased overall (Δ Ki67 = -0.29%, p=0.003), but the effect was restricted to women with baseline Ki67 ≥ 0.5% (n=38, Δ Ki67 = -0.78%, p=0.0002); no significant change occurred with baseline Ki67 < 0.5 (Δ Ki67 = 0.19%, p=0.23). Δ Ki67 was inversely proportional to baseline Ki67. RNA-seq was successful for 171 benign tissue samples (including 53 PreTam-OnTam pairs). After edgeR normalization (>14,600 genes), PreTam vs OnTam comparison across 33 pairs with baseline Ki67 ≥ 0.5% yielded 66 differentially expressed genes (fold-change > 2 and p<0.01). At p<0.01, ranked gene set enrichment analysis revealed 27 gene sets enriched for reduced expression with Tam (with top-ranked gene set related to steroid hormone biosynthesis) and 59 gene sets enriched for increased expression with Tam (with top-ranking gene sets related to B cell and T cell receptor signaling, regulation of cell cycle, and other immune-related pathways). To identify predictors of response, we correlated baseline PreTam gene expression with Δ Ki67 in 37 women with available baseline PreTam RNAseq and Δ Ki67 data. Partial correlation analysis (via ‘ppcor’ package, adjusted for library qubit) revealed 73 genes with significant positive correlation (rho > 0.50) and 14 genes with significant negative correlation (rho < -0.50) with Δ Ki67 (p<0.01). At p<0.01, ranked gene set enrichment analysis yielded 67 gene sets enriched with negative correlation (i.e. increased expression associated with a reduction in Ki67), including pathways related to ribosome biogenesis, DNA recombination, and nucleic acid metabolic processes; there were 62 gene sets enriched for positive correlation (i.e. decreased expression associated with a reduction in Ki67), including pathways such as VEGF and ERBB signaling. Our data support (i) baseline Ki67 ≥ 0.5 % and (ii) an 87-gene baseline signature as complementary biomarkers of tamoxifen response. Prospective validation of this combined assay could target tamoxifen to the women most likely to benefit, potentially overcoming a major barrier to chemoprevention uptake. Citation Format: S. J. Winham, C. Wang, Y. Liu, B. M. McCauley, D. J. Tabrizi, D. L. Gehling, J. L. Fischer, L. R. Seymour, M. H. Solanki, M. E. Sherman, K. R. Lohani, T. L. Hoskin, D. C. Radisky, A. C. Degnim. Gene expression signatures of beneficial response to tamoxifen for breast cancer prevention [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS3-01-18.
PS2-05-23: Immune Heterogeneity in Breast Cancer Natural History: Benign Breast Disease to Breast Cancer
Zhang, A., Cozzo, A., Olsson, L., Kirk, E., Gao, X., Nyante, S., Calhoun, B., Vierkant, Rob, Sherman, M., Troester, M., Cozzo, Alyssa J. , Olsson, L.T, Kirk, E.L., Nyante, Sarah J. , Vierkant, Robert A., Sherman, Mark E.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PS2-05-23-PS2-05-23

10.1158/1557-3265.sabcs25-ps2-05-23 Get It

Abstract Benign breast disease (BBD) confers elevated risk for breast cancer, yet current tools lack precision in identifying lesions likely to progress. Immune mechanisms may influence progression, but the spatial and molecular features of immune responses in BBD versus invasive cancer remain poorly characterized. We applied Digital Spatial Proteomics (DSP) to evaluate immune-related protein expression across 1,540 regions of interest (ROIs) from breast tumors (n=58, Carolina Breast Cancer Study [CBCS]), a UNC BBD cohort (n=20), and a Mayo BBD cohort (n=177). Using Consensus Clustering in CBCS and UNC BBD, we identified two stable immune phenotypes: “High Immune,” enriched in tumors and high-risk benign lesions, and “Quiet Immune,” predominant in low-risk BBD. ROIs were classified by immune marker expression, and patients were labeled as “High” if ≥50% of their ROIs were High Immune. In CBCS, High Immune profiles were associated with ER-negative status (OR=2.92 [0.99-8.65] participant-level; OR=3.28 [1.34-8.04] ROI-level). In BBD, High Immune profiles trended toward higher odds of high-risk lesions (OR=1.00 [0.15-6.70] participant-level; OR=1.68 [0.57-4.97] ROI-level), though this pattern was not replicated in the Mayo cohort. BBD samples exhibited substantial spatial heterogeneity in immune expression (40% within-patient ROI agreement vs. 74% in tumors), potentially limiting biomarker reliability. Nonetheless, four immune proteins (CD44, CD80, CD14, CD66b) were significantly associated with future cancer development in the Mayo cohort, though these findings require validation due to within-person variability. Our findings highlight the challenges posed by spatial heterogeneity in assessing immune biomarkers in BBD and suggest that immune activation may emerge later in disease progression. These results raise important questions about the timing and consistency of immune responses in the natural history of breast cancer. Citation Format: A. Zhang, A. Cozzo, L. Olsson, E. Kirk, X. Gao, S. Nyante, B. Calhoun, R. Vierkant, M. Sherman, M. Troester. Immune Heterogeneity in Breast Cancer Natural History: Benign Breast Disease to Breast Cancer [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PS2-05-23.
Abstract PD4-02: An AI algorithm for breast cancer detection improves future BC risk prediction among women with benign breast disease
Vachon, C. M., Winham, S., Jensen, M., Hursh, D., Norman, A., Fischer, Jessica, Schrup, S., Seymour, L., Gehling, Denice, Nyante, S., Troester, M. A., Karssemeijer, Nico , Vierkant, R., Radisky, D., Scott, C., Maimone, S. I., Degnim, Amy C., Sherman, M. E., Jensen, Michael A. , Pacheco-Spann, Laura M. , Norman, Aaron D. , Seymour, Lisa R. , Nyante, Sarah J. , Vierkant, Robert A. , Radisky, Derek C. , Maimone, Santo , Degnim, Amy C. , Sherman, Mark E.

Mayo Clinic

Clinical Cancer Research | February 17, 2026 | Volume: 32 | Issue: 4_Supplement | Pages: PD4-02-PD4-02

10.1158/1557-3265.sabcs25-pd4-02 Get It

Abstract Background: Artificial intelligence (AI) algorithms based on deep learning approaches show promise in improving breast cancer (BC) detection on mammography and may also improve prediction of future BC risk compared with clinical risk prediction models. Historical clinical risk prediction models underperform among women with BBD; however, AI models for BC detection on mammography have not been tested among women at elevated BC risk due to benign breast disease (BBD). We evaluated if an AI cancer detection algorithm can aid BC risk prediction among women with BBD. Methods: We examined women without a prior BC who had an initial BBD biopsy at Mayo Clinic, Rochester, between 2002 and 2013. Incident BC occurring after BBD was identified using the Mayo Tumor Registry and supplemented by follow-up questionnaires. Only women with a full field digital mammogram at least 2 years prior to BC diagnosis were eligible. A breast pathologist evaluated BBD according to increasing severity, as non-proliferative (NP), proliferative disease without atypia (PDWA) or atypical hyperplasia (AH). AI malignancy scores derived from the Transpara detection algorithm (1-10) and volumetric percent density (VPD) from Volpara (per one standard deviation, SD) were assessed from mammograms close to BBD diagnosis. Cox proportional hazards regression models were applied to estimate hazard ratios (HRs) with 95% Confidence Intervals (CIs), adjusted for age and BMI. C-statistics were estimated to assess the contribution of each factor to BC risk prediction. Likelihood ratio tests (LRTs) and bootstrapping methods were used to compare model performance with the addition of AI malignancy score. Results: The BBD cohort with mammography consisted of 3,125 women followed for a median 12.9 years, with 250 incident BC. Of these, 221 BC occurred at least two years after the mammogram and were used in analyses. As expected, increased BC risk was associated with BBD severity [for AH HR=3.18 (95%CI: 2.04, 4.95) and for PDWA HR=1.59 (95%CI: 1.17, 2.14) compared to NP] and with higher VPD [HR=1.24 per SD (95% CI: 1.05, 1.45)] (Table ). The AI-malignancy score alone was also associated with BC risk [HR=1.16 per 1 unit score (95%CI: 1.09,1.23)] and showed similar discriminatory accuracy [C-statistic=0.626 (95%CI: 0.586, 0.665)] as the model with BBD severity and VPD combined [C-statistic=0.627, (95%CI: 0.585, 0.669)] (Table ). In models with BBD severity and VPD, the AI-malignancy score was an independent risk factor for BC [HR=1.14 (95%CI: 1.07, 1.21); PLRT<0.001] but only achieved a marginally significant improvement in discriminatory accuracy [C-statistic=0.651 (0.609, 0.693), ΔC-statistic=0.024 (95% CI: 0.000, 0.047)]. Conclusion: In this preliminary study, an AI BC detection algorithm achieved similar performance in predicting future BC risk compared to established risk factors. Citation Format: C. M. Vachon, S. Winham, M. Jensen, D. Hursh, L. Pacheco-Spann, A. Norman, J. Fischer, S. Schrup, L. Seymour, D. Gehling, S. Nyante, M. Troester, N. Karssemeijer, R. Vierkant, D. Radisky, C. Scott, S. I. Maimone, A. Degnim, M. Sherman. An AI algorithm for breast cancer detection improves future BC risk prediction among women with benign breast disease [abstract]. In: Proceedings of the San Antonio Breast Cancer Symposium 2025; 2025 Dec 9-12; San Antonio, TX. Philadelphia (PA): AACR; Clin Cancer Res 2026;32(4 Suppl):Abstract nr PD4-02.
A novel approach to defining progression in MDS and precursor myeloid conditions in the MDS Natural History Study
DeZern, A. E., Otterstatter, Michael , Abel, Gregory A., Padron, Eric , Deeg, H. Joachim, Baghdadi, Tareq Al, Liu, Jane Jijun, Zhang, L, Kroft, Steven H. , Harrington, Alexandra M., Foran, J., Komrokji, Rami S., Starczynowski, Daniel T, Gore, Steven D, Saber, Wael, Bejar, Rafael, Lindsley, R. Coleman, Sherman, Seth, Lee, Cecilia , DiFronzo, Nancy, Sekeres, Mikkael A, Zhang, Ling , Gillis, Nancy , Otterstatter, Michael , Deeg, H Joachim , Zhang, Ling , Kroft, Steven H , Komrokji, Rami S , Bejar, Rafael , Lindsley, R Coleman , Sherman, Seth , Sekeres, Mikkael A , Baghdadi, Tareq Al , Dezern, Amy Elizabeth , Abel, Gregory A. , Deeg, H. Joachim , Xie, Zhuoer , Moscinski, Lynn C. , Foran, James M. , Komrokji, Rami S. , Starczynowski, Daniel T. , Gore, Steven D. , Saber, Wael , Walter, Matthew J , Sekeres, Mikkael A.

Mayo Clinic

Blood Advances | February 11, 2026 | Volume: 10 | Issue: 8 | Pages: 2743-2753

10.1182/bloodadvances.2025018770 | PMID 41671442 Get It

Abstract Patients at risk for progression from myeloid precursor states (idiopathic cytopenia of undetermined significance [ICUS] and clonal cytopenia of undetermined significance [CCUS]) to myelodysplastic syndrome (MDS) are not well defined. Epidemiologic risk factors, clonal changes for MDS development, and evolution from one MDS state to another were available in the MDS Natural History Study (NHS), a prospective cohort enrolled at diverse US sites. Extensive clinical data and biospecimens were collected at baseline and follow-up. A total of 1177 (56%) individuals with MDS or MDS-related precursor conditions (ICUS/idiopathic dysplasia of undetermined significance [IDUS], CCUS, and MDS/myeloproliferative neoplasm overlap) were enrolled and diagnosed in the MDS NHS. The median age was 74 years, with 89% aged ≥60 years, and most were male patients. Median follow-up time was 1.6 years and was similar among ICUS/IDUS, CCUS, and MDS. During follow-up period, 68% of participants terminated the study, 35% died, and 38% had disease progression. Using a refined clinical definition of progression, the greatest proportion of progression was observed among higher-risk-MDS (116 [73%]), followed by lower-risk-MDS (170 [52%]); fewer progression events were observed among participants with CCUS (65 [22%]) and ICUS/IDUS (46 [17%]). Predictors of progression are delineated, including female sex, higher quantity of mutations, the presence of TP53 mutation, and poor/very poor cytogenetic score. Based on these prospective data, guidelines for clinical management including monitoring and surveillance are outlined. The MDS NHS provides real-world data to illustrate how clinical and genotypic differences inform the classification, disease course, and approach to therapy, with informed monitoring guidelines for patients. This trial was registered at www.ClinicalTrials.gov as NCT02775383.
The Sport Publication Observational Research Tool (SPORT): An Objective Tool to Score the Methodological Quality of Observational Clinical Sports Medicine Research
Kuhn, Andrew W. , Inclan, Paul M. , Haider, Ameer A. , Christy, Michele, Dunn, Warren, Alberton, Laura A. , Allen, Christina, Anderson, Kyle, Andrews, James, Azar, Fred, Baer, Geoffrey S. , Banffy, Michael B. , Bedi, Asheesh , Brockmeier, Stephen F., Brophy, Robert H. , Bush‐Joseph, Charles A., Carey, James R. , Carter, Thomas, Cohen, Steven, Farrow, Lutul D. , Flanigan, D. Preston, Franklin, Corinna C. , Hame, Sharon L. , Ioannis, Terzidis, Joseph, Sheeba, Kenter, Keith , Koh, Jason R., Krych, Aaron, LeClere, LT Lance, Levy, Bruce, McAllister, David, Morganti, Christina, Musahl, Volker , Nelson, Bradley , Noyes, Frank, Owens, COL Brett D., Pace, Lee, Paulos, Lonnie E., Rodeo, Scott, Safran, Marc, Savoie, Felix H. , Shelbourne, Donald K., Sherman, Seth L. , Singer, Ken, Smith, Matthew, Sonnery-Cottet, Bertrand, Spiker, Andrea M. , Stuart, Michael, Warren, Russell, Wittstein, Jocelyn R. , Wolcott, Michelle L., Wright, Rick, Matava, Matthew J. , Sherman, Seth L. , Kuhn, Andrew W , Dunn, Warren R., Brockmeier, Stephen F. , Brophy, Robert H. , Carey, James, Cohen, Steven B. , Flanigan, David, Krych, Aaron J. , LeClere, Lance E. , Lee, Cassandra Alda , Levy, Bruce, McAllister, David R. , Medvecky, Michael J. , Owens, Brett D. , Pace, J Lee , Redler, Lauren H. , Rodeo, Scott A. , Sonnery‐Cottet, Bertrand

Mayo Clinic

Orthopaedic Journal of Sports Medicine | February 6, 2026 | Volume: 14 | Issue: 2 | Pages: No page available

10.1177/23259671251380883 | PMID 41660291 Get It

Background: A critical component of conducting systematic reviews or meta-analyses is assessing the methodological quality and bias of included studies. Several methodological quality assessment tools have been developed; however, these tools may not be relevant to observational sports medicine research, which carries numerous unique nuances and biases. Purpose: To develop the Sport Publication Observational Research Tool (SPORT), which evaluates and scores the methodological quality of observational sports medicine research. Study Design: Consensus statement. Methods: SPORT was developed through a modified Delphi approach involving members from the Herodicus Society and The FORUM. All active members were invited to participate in the process aimed at building consensus on SPORT content and scoring. After finalizing SPORT, a power analysis led to the independent selection of 55 observational clinical sports medicine studies, which were scored twice by 4 reviewers of varying training levels. Interrater and intrarater reliability for SPORT was assessed using intraclass correlation coefficients (ICCs). The distribution and percentiles for total SPORT score across the 55 studies were calculated. SPORT was also compared with the methodological index for non-randomized studies (MINORS), a commonly utilized quality assessment tool. Results: A total of 51 members participated and achieved 100%, 100%, 98.0%, and 98.0% completion rates for rounds 1 through 4, respectively. The final SPORT included 19 subscores related to methodological quality and bias and achieved 94% consensus approval. Mean SPORT completion time was 6 minutes and 19 seconds per study, which varied significantly by reviewer training level. The subscore "peer review" demonstrated unacceptable reliability and was removed. The remaining 18 subscores exhibited ICC ranges of 0.599 to 0.955 for interrater reliability and 0.530 to 0.936 for intrarater reliability. Total SPORT score demonstrated excellent agreement, for interrater (ICC, 0.967) and intrarater reliability (ICC, 0.966). Median SPORT score across the 55 studies was 20.0 and skewed toward lower scores. There was a moderate significant correlation between SPORT and MINORS ( r [53] = 0.575; P < .001). Conclusion: An objective tool to assess the methodologic quality of observational sports medicine research (SPORT) was successfully developed through a modified Delphi approach with numerous content experts in the field. This tool may be useful in assessing the methodological quality of primary observational sports medicine studies included in systematic reviews and meta-analyses.
Functional genomics identifies therapeutic options, biomarkers, and resistance mechanisms for high-grade gliomas
Lin, Wan-Hsin, Kosari, Farhad , Smadbeck, James B. , Barrett, Michael T. , Feathers, Ryan, Hall, Jamie, Sadeghian, Dorsay , Johnson, Sarah H. , Harris, Faye R. , Berry, Taylor, McCune, Alexa, Murphy, Stephen James, Kinsella, Lindsey, Ensign, Shannon P. Fortin, Yang, Lin , Emanuel, Angela, Jones, Leila A., Schaefer-Klein, Janet, Ida, Cristiane M., Sherman, Wendy, Porter, Alyx B. , Rosenfeld, Steven, Kizilbash, Sani H., Jaeckle, Kurt A. , Mrugala, Maciej M., Borad, Mitesh, Bendok, Bernard R., Quiñones-Hinojosa, A., Cheville, John C. , Vasmatzis, George , Anastasiadis, Panos Z. , Ensign, Shannon P. Fortin , Mansfield, Aaron S , Ensign, Shannon P. Fortin , Sotiriou, Sotiris , Haydu, Lauren E. , Moniz‐Garcia, Diogo , Ida, Cristiane M., Salomao, Marcela , Kizilbash, Sani H. , Mrugala, Maciej M., Mansfield, Aaron S. , Borad, Mitesh J. , Bendok, Bernard R. , Burns, Terry C. , Quiñones‐Hinojosa, Alfredo

Mayo Clinic

No container title available | February 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.02.01.701806 | PMID 41676502 Get It

Abstract High-grade gliomas (HGGs) are aggressive tumors with poor outcomes and limited treatment options. Here, we combined genomic and transcriptomic tumor profiling with drug testing in a patient-derived 3-dimensional culture model to identify individualized treatments and predictive biomarkers. Activity of single agents targeting frequently dysregulated glioma pathways was relatively poor ex vivo and generally reflected historical patient data. However, compounds targeting PI3K, epigenetic, and survival/senescence signaling were effective in some cases. Drug sensitivity correlated with transcriptional rather than genomic features and suggested heterogeneity as a resistance mechanism. Bromodomain and extraterminal domain inhibition was particularly effective in tumors enriched in the mesenchymal transcriptional subtype, promoted proneural transition, and was overcome by upregulated PI3K signaling. Notably, combinations were largely effective, with 6 strategies exhibiting stronger efficacy than corresponding single agents in most cases (58-77%). This study identifies HGG vulnerabilities and associated biomarkers, resistance mechanisms, and effective combination strategies that warrant further clinical validation. Graphical Abstract
Long‐term amyloid PET and MRI outcomes in a menopausal hormone therapy trial
Kantarci, Kejal, Tosakulwong, Nirubol , Fought, Angela J. , Schwarz, Christopher G, Kendall-Thomas, June, Min, Paul H., Lowe, VJ, Jack, Clifford R, Kapoor, Ekta, Fields, Julie A. , Bailey, Kent R., James, Taryn T. , Faubion, Laura L. , Ra, Lobo, Manson, JoAnn E, Pal, Lubna, Hammers, Dustin B, Malek-Ahmadi, Michael, Cedars, Marcelle I., Naftolin, Frederick N, Santoro, N., Miller, V. M., Harman, Sherman, Gleason, Carey E, Min, Hoon‐Ki , Min, Paul, Min, Hoon-Ki Paul , Kantarci, Kejal , Kara, Firat , Schwarz, Christopher G. , Senjem, Matthew L. , Kendall‐Thomas, June, Jack, Clifford R. , Kapoor, Ekta , Manson, JoAnn E. , Pal, Lubna , Hammers, Dustin B , Brinton, Eliot A. , Malek‐Ahmadi, Michael , Cedars, Marcelle I. , Naftolin, Frederick , Harman, S. Mitchell , Dowling, N. Maritza , Gleason, Carey E.

Mayo Clinic

Alzheimer's & Dementia | January 31, 2026 | Volume: 22 | Issue: 2 | Pages: No page available

10.1002/alz.71067 | PMID 41618732 Get It

Abstract INTRODUCTION Associations of short‐term use of menopausal hormone therapy (mHT) with Alzheimer's disease (AD) and structural magnetic resonance imaging (MRI) biomarkers were investigated 10 years after an mHT trial. METHODS Recently menopausal women with good cardiovascular health were randomized to oral conjugated equine estrogens (oCEE) or transdermal 17β‐estradiol (tE2) and micronized progesterone, or placebo for 4 years. Amyloid beta (Aβ) on positron emission tomography, hippocampal atrophy, and dorsolateral prefrontal cortex thickness on MRI were assessed 10 years after completion of the mHT trial ( n = 266). RESULTS Aβ and structural MRI biomarkers were not different in the oCEE and tE2 groups compared to placebo. Apolipoprotein E ε4 status did not modify the findings. DISCUSSION There was no evidence of adverse effects or benefits associated with 4 years of use of oral or transdermal mHT on Aβ and structural MRI biomarkers in relatively healthy women, 10 years after mHT. Findings support the long‐term safety of short‐term use of mHT on brain health. CLINICAL TRIALS REGISTRATION NCT00154180 Kronos Early Estrogen Prevention Study (KEEPS) Highlights There were no menopausal hormone therapy–related adverse effects or benefits on amyloid beta and magnetic resonance imaging biomarkers in the long term. Apolipoprotein E ε4 carrier status did not modify these findings. Findings align with neutral cognitive and cerebrovascular outcomes in this cohort.
Evaluating the Impact of Financial Navigation on Financial Catastrophe and Distress for Cancer Care: A Randomized Control Trial- COST-FIN
Afolaranmi, Oluwasegun, Guiterrez, George, Oyewole, Adewale Isaiah, Ebekue, Dorcas Olaide, Adegbite, Zainab, Awe, Clement, Ogunniyi, Titilope, Opeyemi, Akinlusi, Uwechue, Frances I, Sherman, Dan, Lambert, Clara N. , Adedayo, Joseph, Diaz, Kristina, Christian, Elizabeth Nicole, Akin-Adigun, Olufemi, Okeke, Sophia , Knapp, Gregory, Dare, Anna Yunita, Aduloju, Toluwanimi, Akinwumi, Moyinoluwa, Nwogu, Chukwumere E., Hirschhorn, Lisa R, Adin-Cristian, Andrei, Iwuji, Chinenye , Ilegbune, Oge, Jimoh, Mutiu , Chugani, Bindiya , Oputa, Olise, French, Dustin D. , Ackermann, Ron, Murphy, Robert, Seddoh, Anthony Theophilus, Kingham, Peter Thomas, Lumati, Juliet S., Afolaranmi, Oluwasegun , Afolaranmi, Oluwasegun , Lumati, Juliet S , Sohail, Amir Humza , Wuraola, Funmilola Olanike , Caputo, Matthew , Gutierrez, George A., Nwankwo, Chinyere, Sherman, Daniel, Abdulkareem, Fatimah Biade , Akingbola, Adewunmi , Knapp, Gregory , Dare, Anna, Kohli-Lynch, Ciaran Navin , Chen, Ruohui , Nwogu, Chukwumere E. , Hirschhorn, Lisa R. , Alani, Jimoh Mutiu, Murthy, Shilpa Shree , Ackermann, Ronald T. , Murphy, Robert L. , Kingham, T. Peter , Alatise, Olusegun Isaac

Mayo Clinic

No container title available | January 21, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7686399/v1 | PMID 41646304 Get It

Abstract Background: As with most Sub-Saharan African countries, Nigeria has a rising incidence of cancer, with disproportionate mortality rates. The financial burden of cancer care often results in catastrophic healthcare spending, leading to treatment refusal, disruption, and discontinuation. This is particularly significant in Nigeria, where nearly all patients are uninsured, and out-of-pocket costs often exceed households’ ability to pay. Financial Navigation Programs (FNPs) have been shown to mitigate treatment-related financial toxicity in cancer care and reduce treatment abandonment, but there is a paucity of high-quality data on this intervention in resource-constrained settings. Here, we present a randomized controlled trial to evaluate the impact of a novel FNP in Nigeria. Methods: We designed the COST-FIN trial, a multi-site pragmatic single-blinded randomized controlled trial of newly diagnosed (<6 weeks from diagnosis) adults (≥18 years) with breast, colorectal, or prostate cancer at two tertiary cancer centers in Nigeria. Participants (n=200) will be randomized (1:1) to either the intervention (FNP) or the control arm and followed for 12 months. Data on key individual, treatment, and financial parameters will be collected via structured interviews and chart abstraction at baseline, 3, 6, and 12-month follow-up. In addition, participants randomized to the FNP will receive a tailored financial literacy assessment, financial planning support, and enhanced access to resources by trained financial navigators. Primary and secondary outcomes are Financial Catastrophe (FC) and Financial Distress (FD), respectively. Exploratory outcomes will include cost-related non-adherence and cost-effectiveness of the program. An interim analysis will be conducted when 50% of the estimated accruals reach 6 months of follow-up, with crossover if compelling evidence of benefit is demonstrated at that time point. All participants will be followed for 12 months from recruitment. Discussion: This first-of-its-kind study will provide evidence on the role of FNP in potentially eliminating financial barriers to cancer care in Nigeria. Given the country’s renewed interest in cancer control through the passage of the National Cancer Control Plan, findings from this study have the potential to influence policy reform and set the stage for further studies to evaluate the scalability and implementation of similar interventions in resource-limited settings. Trial registration : ClinicalTrials.gov NCT06630962. Oct 8, 2024 (https://clinicaltrials.gov/study/NCT06630962)